Commercial strain-derived clinical Saccharomyces cerevisiae can evolve new phenotypes without higher pathogenicity by Pfliegler, Valter Péter et al.
1 
 
Commercial strain-derived clinical Saccharomyces cerevisiae can evolve new phenotypes 1 
without higher pathogenicity 2 
 3 
Walter P. Pfliegler1,2*, Enikő Boros1, Kitti Pázmándi3, Ágnes Jakab1, Imre Zsuga1, Renátó 4 
Kovács4,5, Edit Urbán6, Zsuzsa Antunovics7, Attila Bácsi3, Matthias Sipiczki7, László 5 
Majoros4, István Pócsi1 6 
1Department of Biotechnology and Microbiology, University of Debrecen, Debrecen, 7 
Hungary; 8 
2Postdoctoral Fellowship Programme of the Hungarian Academy of Sciences (MTA), 9 
Budapest, Hungary; 10 
3Department of Immunology, University of Debrecen, Debrecen, Hungary; 11 
4Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary 12 
5Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary; 13 
6Institute of Clinical Microbiology, University of Szeged, Szeged, Debrecen; 14 
7Department of Genetics and Applied Microbiology, University of Debrecen, Debrecen, 15 
Hungary 16 
 17 
*Correspondence: Walter P. Pfliegler 18 
Dept. of Biotechnology and Microbiology, University of Debrecen, Egyetem tér 1., Debrecen, 19 
H4032, Hungary. Tel: +3652512900/62492; Fax: +3652512925; Email: 20 
pfliegler.valter@science.unideb.hu 21 
22 
2 
 
Abbreviations: AmB, amphotericin B; Flu, fluconazole; gDNA, genomic DNA; MIC, 23 
minimal inhibitory concentration; MSB, menadione sodium bisulfite; mtDNA, mitochondrial 24 
DNA; PBMC, Peripheral blood mononuclear cells; TNF-α, Tumor necrosis factor alpha. 25 
 26 
Keywords: baking yeast, commensal, microevolution, mycobiom, probiotic 27 
28 
3 
 
Abstract 29 
Scope: Saccharomyces cerevisiae is one of the most important microbes in food industry, but 30 
there is growing evidence on its potential pathogenicity as well. Its status as a member of 31 
human mycobiome is still not fully understood. 32 
Methods and results: In this study, we characterise clinical S. cerevisiae isolates from 33 
Hungarian hospitals along with commercial baking and probiotic strains, and determine their 34 
phenotypic parameters, virulence factors, interactions with human macrophages, and 35 
pathogenicity. Four of the clinical isolates could be traced back to commercial strains based 36 
on genetic fingerprinting. Our observations indicate that the commercial-derived clinical 37 
isolates have evolved new phenotypes and show similar, or in two cases, significantly 38 
decreased pathogenicity. Furthermore, immunological experiments revealed that the 39 
variability in human primary macrophage activation after co-incubation with yeasts is largely 40 
donor- and not isolate-dependent. 41 
Conclusion: Isolates in this study offer an interesting insight into the potential microevolution 42 
of probiotic and food strains in human hosts. These commensal yeasts display various 43 
changes in their phenotypes, indicating that the colonization of the host does not necessarily 44 
impose a selective pressure towards higher virulence/pathogenicity. 45 
46 
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1. Introduction 47 
The roles of Saccharomyces cerevisiae in producing fermented beverages and in breadbaking 48 
have made this yeast one of the most important microbes throughout human history [1, 2]. S. 49 
cerevisiae is a domesticated species with different clades adapted to different fermentation 50 
technologies [1, 3]. Its use in various branches of the food industry leads to frequent human 51 
exposure to S. cerevisiae, and besides probiotics, food-borne yeasts may also have beneficial 52 
health effects [4]. The potential of this yeast to colonize the human body has long been 53 
suspected, although its status as a transient species [5, 6] or established nature [7, 8] in the 54 
human mycobiome is still unclear. S. cerevisiae colonization of the gastrointestinal tract may 55 
be locally frequent [9]. 56 
Although S. cerevisiae is generally recognized as safe, its colonization of the human body, 57 
whether transient or long lasting, may occasionally result in infections (mycoses) [2, 10, 11]. 58 
Opportunistic Saccharomyces infections have become known and reported from patients from 59 
a wide range of age groups and underlying diseases [12–16], including systemic mycosis in 60 
immunocompromised patients [17]. Multiple methods are in use to characterize the traits of 61 
opportunistic pathogenic yeasts, and many of them are referred to as pathogenicity or 62 
virulence factors. However, often there is a considerable overlap in clinical and non-clinical 63 
strains in virulence traits, as recently reviewed [18]. Besides surveying virulence factors and 64 
their correlation with pathogenic potential, understanding the origin of human-related S. 65 
cerevisiae isolates and their relations to the different industrial and natural clades of the 66 
species can help us to shed light on how this yeast might evolve commensalism or 67 
pathogenicity. 68 
Recently, molecular phylogenetic investigations on the global diversity of the species have 69 
identified human-adapted S. cerevisiae clades that have arisen from multiple opportunistic 70 
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colonization events [2, 3, 19, 20]. Most of the clinical yeasts were shown to be genetic 71 
mosaics, but several isolates were nested in the non-hybrid Wine/European clade of the 72 
species [2]. 73 
Opportunistic pathogenic S. cerevisiae isolates derived from baking yeasts have also been 74 
identified from patients with or without occupational exposures to baker's yeasts [21–27], 75 
although in several cases, the clinical isolates were plausibly commensal [22]. Potential risks 76 
of food yeast products were recently reviewed [28]. 77 
Growing evidence on the pathogenic potential of probiotic-derived S. cerevisiae opportunistic 78 
pathogens is also available. S. cerevisiae probiotics and biotherapeutic agents are marketed as 79 
'S. boulardii' and advised for patients with dysentery [29]. These strains are asporogenous 80 
natural isolates, with moderate [30] or often considerable virulence factors [31, 32]. 81 
Fungaemia related to a commercial probiotic strain was reported in an intensive care unit and 82 
in the case of premature neonates [33, 34]. Consequently, caution was proposed for 83 
immunosuppressed patients regarding the use of such probiotics [14, 31]. In the case of 84 
immunocompetent hosts, intravenous inoculation with probiotics caused septic shock that was 85 
spontaneously cured, indicating that these strains are not highly virulent pathogens [35, 36]. 86 
Regardless of whether different Saccharomyces isolates of the human mycobiome are 87 
exogenous opportunists or true commensals in the gut, studying their adaptations related to 88 
virulence, possible antimycotic resistance or their interactions with the immune system is 89 
important. In our study, we characterized clinical S. cerevisiae isolates from Hungary along 90 
with dietary and probiotic strains available in the country with genotyping methods and 91 
assessed their various phenotypic features and immunostimulatory activity, in order to 92 
determine whether the clinical isolates can be traced back to the commercial strains and if so, 93 
whether their phenotypes show consistent differences. Using the characterization of 94 
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commercial strains and four genetically related isolates, we show that these commercial-95 
derived clinical S. cerevisiae are apparently subjected to microevolution in the human host. 96 
 97 
2. Materials and Methods 98 
 99 
Strains, isolates and identification. Isolates were obtained as single-cell colonies from patients 100 
in the university clinics in Debrecen and Szeged (Hungary) (isolation data is listed in 101 
Supplementary File S1). Strains of baker's, wine and probiotic yeasts were obtained 102 
commercially and were given individual identifiers (Supplementary File S1). 103 
Genetic characterization. Interdelta fingerprinting [37] was used for strain typing and applied 104 
to establish genetic relatedness of strains and isolates. The strain-isolate pairs with identical or 105 
near identical patterns were considered having a very recent common (commercial) ancestor. 106 
These yeasts were further subjected to karyotyping, RAPD-PCR, microsatellite PCR, and 107 
mitochondrial DNA-RFLP to confirm their genetic similarity and close relatedness. Methods 108 
for typing are listed in Supplementary File S1. 109 
Phenotypic characterization. The sporulation capability, colony morphology, pseudohyphal 110 
and invasive growth, susceptibility to antifungal and oxidative stress generating agents, 111 
growth under osmotic, chemical and high temperature stress conditions, extracellular 112 
hydrolytic enzyme production, and hemolytic activity were assessed for all yeast isolates and 113 
strains to provide a broad overview of their phenotypic characteristics, with methods 114 
described in Supplementary File S1 in detail.  115 
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Damage assay was conducted using a Cytotoxicity Detection Kit - LDH (Hoffmann-La 116 
Roche, Basel, Switzerland) with Caco-2 cell monolayer in 96-well plates following the 117 
manufacturer's protocol as described in Supplementary File S1. 118 
Insect pathogenicity model. The Galleria mellonella larva pathogenicity model [38] was used 119 
to assess the pathogenicity of the strains and isolates in vivo. This model enables the rapid 120 
assessment of the pathogenicity of opportunistic fungi (e.g. Candida spp) on a large number 121 
of infected hosts and is comparable to murine models [39]. Details of the experiments are 122 
listed in Supplementary File S1. 123 
Immunological experiments. Phagocytosis assay using flow cytometry and phenotypic and 124 
functional analysis of yeast-exposed human primary macrophages differentiated from four 125 
healthy donors' PBMCs were used to assess immune activation by the individual strains and 126 
isolates. Experimental procedures and PBMC isolation and macrophage differentiation are 127 
described in Supplementary File S1. 128 
Statistics. Measurements carried out in triplicates (hemolysis, extracellular enzyme activity, 129 
damage and phagocytosis assays) and quadruplicates (macrophage phenotype) allowed 130 
statistical comparisons among different yeast strains and isolates, as described in 131 
Supplementary File S1. 132 
 133 
3. Results 134 
 135 
Fingerprinting and relations among the strains and isolates 136 
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For strain typing, the resolution of interdelta fingerprinting and microsatellite typing for two 137 
loci were compared. All three combinations of interdelta PCR resulted in distinct fingerprints 138 
for all commercial yeasts, while both microsatellite analyses were unable to distinguish 139 
between two of the baking strains (BY2 and BY3) (Supplementary File S2). We thus relied 140 
primarily on interdelta fingerprinting to assess the genetic relatedness among the commercial 141 
strains and the clinical isolates, similarly to previous works [26-27]. The strains and isolates 142 
with identical or highly similar fingerprinting patterns (Figure 1 a-c) were further 143 
characterized by microsatellite typing, RAPD-PCR, mtDNA-RFLP, and karyotyping (Figure 144 
1 d-h). 145 
The combined use of three primer combinations for interdelta-PCR resulted in a dendrogram 146 
that showed the following clusterings of commercial and clinical yeasts: the isolate Sz1 (from 147 
cervix) with the baking strain BY1; the isolates Sz7 and Sz9 (from stomach and throat, 148 
respectively) with BY2; and isolate DE27020 (from bronchus) with PY1 (Supplementary File 149 
S1-2). Pattern identity (isolates Sz7, Sz9, DE27020) or high similarity (isolates Sz1) between 150 
commercial strains and certain clinical isolates strongly implies common ancestry, meaning 151 
that these clinical isolates are derived from commercial yeasts and share very recent common 152 
ancestors with the given batches of commercial yeasts analyzed in this study. The common 153 
ancestors of the commercial-clinical counterparts are plausibly batches of the same 154 
commercial yeasts manufactured earlier (especially in the case of yeasts with pattern identity), 155 
or closely related yeasts commercialized under different trade marks. Furthermore, the 156 
isolates Sz8 and DE27290 were also found to group together with baking strains BY1, BY2 157 
and BY3 (Supplementary File S2), implying some level of genetic relatedness. 158 
Microsatellite, mtDNA-RFLP and RAPD-PCR band patterns were identical in the case of all 159 
commercial-clinical counterparts identified by interdelta analysis. However, mtDNA-RFLP 160 
patterns were also indistinguishable between BY1 and BY2. Microsatellite analysis identified 161 
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tri- and tetraallelic strains and isolates (Supplementary File S2), suggesting poly- or 162 
aneuploidy. Karyotyping produced distinct chromosomal band patterns for the two baking and 163 
the probiotic yeast (Figure 1). All baking yeasts and their clinical counterparts possessed 164 
supernumerary bands in the region of small chromosomes (chromosomes I, VI and III): two 165 
extra bands in the case of BY1 and one in Sz1, and two bands in the case of BY2 and its 166 
counterparts (identical among these yeasts) (Supplementary File S2). Chromosome II showed 167 
size polymorphism when BY1 and Sz1 were compared. An additional supernumerary band 168 
was observed for BY2 and its counterparts between chromosomes V and XI (Supplementary 169 
File S2). Thus, BY2 and its counterparts Sz7 and Sz9, and PY1 and its counterpart DE27020 170 
showed identical karypotypes, whereas BY1 and Sz1 showed occasional polymorphism in 171 
chromosome sizes. 172 
 173 
Characteristics of clinical isolates related to baking yeast strains. 174 
Data on phenotypic features and virulence factors enabled us to compare clinical isolates and 175 
their commercial counterparts (the clinical isolates and the commercial strains that showed the 176 
highest genetic similarity, in some cases identity, with these, viz. PY1 and DE27020; BY1 177 
and Sz1; BY2 and Sz7, Sz9). Table 1 highlights the phenotypic differences between these 178 
strain/isolate pairs. 179 
The isolate Sz1, as compared to the baking yeast BY1 (Table 1), showed decreased 180 
sporulation rate (40% vs. 90%). The pseudohyphae of Sz1 were short, while BY1 possessed 181 
long chain-like pseudohyphae. Sz1 showed reduced growth at 39°C compared to the baker's 182 
strain (Supplementary File S3). Tolerance of sulfite and pH8 stress was higher in Sz1. 183 
Phospholipase activity was not significantly different at 30°C, but at 37°C the baker's strain 184 
showed a significantly higher activity (p<0.01). Higher protease activity (p<0.05) and β 185 
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hemolytic activity (p<0.01) were found in the clinical isolate. Pathogenicity in the insect 186 
model, as well as macrophage phenotypes and phagocytosis after exposure to BY1 and Sz1 187 
were highly similar (Table 1, Supplementary Files S3-S5). 188 
Differences among the clinical isolates Sz7 and Sz9 and the baking strain BY2 included 189 
colony morphology, sporulation ability, cell size, invasive growth into the agar medium, and 190 
tolerance of high temperature (Table 1, Supplementary File S3). Tolerance of sulfite and NaCl 191 
stress was elevated in the case of both clinical isolates. Copper stress tolerance was decreased 192 
in Sz9. Both clinical isolates were unable to grow at pH 8, while BY2 displayed weak growth 193 
(Supplementary File S3). Phosholipase activity of the baker's strain at 37°C was significantly 194 
higher than that of Sz7 (p<0.05). At 30°C, BY2 did not display lipolytic activity, while both 195 
clinical isolates were lipolytic. Proteolytic activity of Sz9 was significantly elevated (p<0.05). 196 
The α-hemolytic activity was elevated in the case of Sz9 and lower in the case of Sz7 after 1 d 197 
(p<0.05), and elevated in the case of Sz7 after 2 d (p<0.05). β-hemolytic activity was 198 
significantly higher in the case of Sz7 (p<0.01) and Sz9 (p<0.001) (Table 1). Pathogenicity in 199 
the Galleria larvae showed remarkable differences between these yeasts. The strain BY2 200 
killed 30 % of the inoculated larvae and the survival rates of Sz7 and Sz9 were significantly 201 
higher: Sz7 killed only 5 % of the larvae (p<0.05) and all larvae inoculated with Sz9 survived 202 
(p<0.01) (Supplementary File S5). Significant differences were not found in the case of 203 
macrophage phenotypes and phagocytosis after exposure to BY2 and the two isolates 204 
(Supplementary Files S3-4). 205 
 206 
Characteristics of the clinical isolate related to the probiotic yeast. 207 
The isolate DE27020 showed minor differences in phenotypes when compared to the 208 
probiotic strain PY1 (Table 1). At 39°C, DE27020 showed stronger growth than PY1 209 
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(Supplementary File S3). Lack of sporulation, colony and pseudohyphal morphology, and cell 210 
size were remarkably similar (Supplementary File S3). The clinical isolate's tolerance to 211 
sulfite and lithium stress was elevated compared to PY1, while other tested stress factors did 212 
not show such differences. Extracellular hydrolase production was highly similar for both 213 
yeasts. Damage assay conducted on Caco-2 epithelial cells revealed an elevated cell damage 214 
(p<0.01) in the monolayer when exposed to DE27020. However, both yeasts caused relatively 215 
low cell death when compared to the high control (Table 1, Supplementary File S3). 216 
Pathogenicity in the larva model was similarly very low in the case of both yeasts 217 
(Supplementary File S5). No significant difference was found when the extent of 218 
phagocytosis or macrophage phenotypes were compared (Table 1, Supplementary Files S3-4). 219 
 220 
4. Discussion 221 
 222 
To determine if any of the clinical isolates can be traced back to commercial S. cerevisiae 223 
strains used in the food industry, we applied interdelta genotyping. This method has been 224 
applied to identify commercial derived clinical isolates before [26-27] and our results showed 225 
that it has a better resolution as microsatellite typing, mtDNA-RFLP or RAPD also applied in 226 
this study. We identified three clinical isolates as baker's yeast- and one as probiotic-derived, 227 
and the similarity between the genotyping profiles enabled us to propose very recent common 228 
ancestry for these clinical yeasts and three of the commercial yeast strain batches used in this 229 
study (common ancestors are plausably batches of the same commercial yeasts manufactured 230 
earlier, especially in the case of identical genotyping markers, or genetically highly similar 231 
commercial yeasts). This genetic relationship among certain isolates and baker's or probiotic 232 
strains was further backed by identical microsatellite alleles, identical RAPD-patterns, 233 
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identical mtDNA-RFLP profiles and identical or highly similar karyotypes. The presence of 234 
two to four microsatellite alleles, occasional changes in interdelta fingerprints, and the small 235 
variations in karyotypes in the case of the baker's yeast BY1 and its clinical counterpart Sz1 236 
suggests that these yeasts possess an polyploid/aneuploid genome that is more prone to 237 
changes than that of the PY1 probiotic yeast's and its clinical counterpart's genome. This 238 
observation of occasional variability that is well known among yeasts subjected to 239 
microevolution in different environments [40,41 and references therein] is also in 240 
concordance with the fact that the baker's yeasts and their counterparts are capable of 241 
sporulation, while PY1 and DE27020 are asporogenous. Additionally, some closely related 242 
clinical isolates of undetermined affilities (viz. Sz2, Sz3, Sz4 and Sz5) also showed no 243 
sporulation (or <1 % sporulation) and these isolates also displayed some differences in 244 
phenotypes but had identical interdelta profiles (Supplementary File S2-5). 245 
Each of the commercial-derived clinical isolates in this study were sampled from different 246 
patients, from anatomical parts such as cervix, stomach, throat, and bronchus, on different 247 
dates and thus represent individual colonization events. None of the patients were diagnosed 248 
with S. cerevisiae fungaemia, thus their isolates may have been either (i) pathogens not 249 
causing fungaemia at the time of sampling; (ii) non-pathogenic yeasts with commensal 250 
adaptations; or (iii) recently ingested commercial strains transiently associated with the 251 
patients. The latter scenario is unlikely as all isolates displayed various phenotypes and often 252 
some level of genetic variability when compared to the genetically most similar commercial 253 
yeasts, thus these isolates have apparently already been subjected to microevolution after the 254 
colonization of the hosts. Additionally, the Galleria pathogenicity model did not indicate high 255 
pathogenicity for the isolates, thus the most likely scenario is a commensal lifestyle. 256 
Phenotypic characterization not only revealed differences between the commercial strains and 257 
their clinical counterparts but also among the clinical isolates, including differences between 258 
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Sz7 and Sz9, two isolates genetically indistinguishable from BY2 (Table 1). Elevated or 259 
impaired growth at higher temperatures, a possible virulence factor of the species [42,43] and 260 
other opportunistic fungi as well, was both found in the case of the isolates, without changed 261 
invasive growth. Similarly to clinical isolates tested previously [43], none of the yeasts in this 262 
study were able to grow at 42°C. As noted before [18], growth and phenotype at temperatures 263 
higher than 37°C may be important, but not crucial in virulence. Sulfite tolerance, 264 
interestingly, was uniformly elevated in the clinical isolates. Only one isolate displayed 265 
changes in lithium and and one in copper tolerance. It is unclear how these traits are related to 266 
pathogenicity but higher lithium and copper tolerance have been found among pathogenic 267 
yeasts [44, 45]. Susceptibility testing to antimycotics or MSB showed only minor differences 268 
among the strains and their clinical counterparts. 269 
Differences in the production of extracellular hydrolytic enzymes were commonly observed: 270 
isolates either showed reduced or unaltered phospolipase activities and elevated or unaltered 271 
protease activities at the host's physiological temperature. Hemolytic activity was more 272 
pronounced in the case of all baker's yeast derived isolates (Table 1). Damage assay with 273 
Caco-2 epithelial cells revealed significant differences only in one strain–isolate pair (PY1 274 
and DE27020). 275 
Pathogenicity of the yeasts in this study was assessed using the Galleria larva model, which is 276 
capable of providing generalized information on the pathogenicity of a wide range of 277 
microorganisms [39, 46]. In our study, only few yeasts were able to significantly decrease 278 
larval survival (Supplementary File S5). PY1 and DE27020, BY1 and Sz1 had no significant 279 
effect on the larvae's survival. Significant pathogenicity was found in the case of the baker's 280 
strain BY2, while it's clinical counterparts were non-pathogenic (isolates Sz7 and Sz9). 281 
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Phagocytosis experiments and characterization of the macrophage activation were carried out 282 
using primary macrophages from three and four (respectively) different healthy donors. 283 
Macrophages are known for their phagocytic activity and antigene presentation in peripheral 284 
tissues, and understanding how they form the first line of defence during yeast infections is 285 
crucial [47, 48]. Our experimental design allowed us to evaluate if the macrophage responses 286 
to yeasts are mostly dependent on the individual strain/isolate or the individual donor. The 287 
latter scenario is backed by our data, as high variances between individual donors were found 288 
(Supplementary Files S3-4). The macrophages of four different donors not only showed 289 
remarkable differences in their activation and phenotypes after co-incubation with a given 290 
yeast, but many yeasts induced relatively weak activation in the case of some donors while 291 
inducing very high relative activation in others. This variability was marked for most of the 292 
tested macrophage features when all 19 yeasts were compared (Supplementary File S4). 293 
These donor-dependent differences (that apparently mask strain and even strain-group level 294 
differences in macrophage activation) have previously not been uncovered, as experiments are 295 
usually conducted using one donor – one yeast strain setups [49, 50]. As proinflammatory 296 
processes have been associated with increased virulence of the species [46], donor dependent 297 
differences in phagocyte activation may be important in future studies on virulent and 298 
avirulent S. cerevisiae. 299 
Relatively rapid microevolutionary changes that influence the biology of opportunistic fungi 300 
have been found previously [51] in the case of other species. To the best of our knowledge, 301 
our results are the first to imply that commercial-derived S. cerevisiae baker's yeasts may 302 
evolve under an apparently commensal lifestyle with altered phenotypes but without elevated 303 
pathogenicity (often clearly decreased pathogenicity). As humans may come into contact with 304 
industrial strains of fungi on a daily basis, assessing the phenotypes, epidemiology and the 305 
potential evolution towards a pathogenic or commensal lifestyle of these fungi is relevant 306 
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from the aspects of clinical as well as evolutionary microbiology. Yeasts are often 307 
excreted/cleared from the human body but their fate is apparently more complex [36, 52, 53]. 308 
Yeasts may also become commensal or opportunistic. These possibilities are summarized in 309 
Figure 2. The phenotypic features including virulence factors observed in the cases of the 310 
commercial-derived isolates in this study might represent responses to adaptive pressures 311 
inside the human host (e.g. changed stress tolerance) or, on the contrary, a relaxed selection 312 
compared to the circumstances under industrial strain selection (e.g. decreased phospholipase 313 
activity). 314 
Yeasts, especially S. cerevisiae are species of clinical interest and simultaneously model 315 
organisms in this field. Here, we have found indication that commercial food strains of the 316 
species are capable of persisting as commensals in different niches of the human body for 317 
periods long enough to allow microevolutionary changes, resulting in isolates possessing 318 
genetic markers identical to, or very similar to commercial strains, but having distinct 319 
phenotypes. The diverse phenotypes of commercial-derived isolates suggest no selective 320 
pressure towards higher virulence and pathogenicity during this process. Further studies 321 
involving phenotypic analysis and genomics of different Saccharomyces strains and isolates 322 
may provide an unprecedented insight into how our most widely used domesticated microbe 323 
evolves in human hosts and help us to better understand its pathogenic potential. 324 
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Figure 1. 487 
Comparison of commercial yeasts' and their clinical counterparts' genotyping profiles. a: 488 
interdelta fingerprinting with primers delta1-2. b: interdelta fingerprinting with primers 489 
delta12-2. c: interdelta fingerprinting with primers delta12-21. d: RAPD pattern with primer 490 
24. e: microsatellite typing for locus YPL009c. f: microsatellite typing for locus YOR267c. g: 491 
mtDNA-RFLP with enzyme RsaI. h: electrophoretic karyotype. Lane 1: BY1. Lane 2: Sz1. 492 
Lane 3: BY2. Lane 4: Sz7. Lane 5: Sz9. Lane 6: PY1. Lane 7: DE27020. 493 
 494 
Figure 2. 495 
Possible outcomes of the intake of S. cerevisiae probiotic and baker's strains: clearence, 496 
commensal, or pathogenic persistence with studies describing these highlighted. Question 497 
mark represents inconclusive records (e.g. the pathogenicity of isolates was not estimated). 498 
 499 
Table 1. 500 
Phenotypic differences in commercial–clinical yeast pairs. Each clinical isolate is compared 501 
to the commercial counterpart. Significant changes in the obtained continuous values, 502 
>twofold differences in MIC values, and differences in stress tolerance, pseudohyphal type, 503 
etc. are indicated. 504 
 505 
Supplementary File S1. 506 
Supplementary File 1: Supplementary materials and methods. 507 
 508 
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Supplementary File S2. 509 
Supplemtary File S2. Comparison of commercial strains using interdelta and microsatellite 510 
typing; interdelta genotyping and dendrogram of the strains and isolates; chromosomal band 511 
patterns and chromosome polymorphisms of the strains and their clinical counterparts. 512 
 513 
Supplementary File S3. 514 
Supplementary file 3. Phenotypic features and macrophage interactions of the commercial 515 
strains and clinical isolates (measurements). 516 
 517 
Supplementary File S4. 518 
Macrophage activation and extent of phagocytosis of the commercial strains and clinical 519 
isolates. Donor-dependent differences are visualized as web graphs of obtained fold-change 520 
values. Phagocytosis visualized with confocal laser scanning microscopy is presented for the 521 
strain PY1. 522 
 523 
Supplementary File S5. 524 
Survival data and statistics of larvae inoculated with different commercial yeast strains and 525 
clinical isolates. 526 
